Opus Genetics, RYZUMVI, Phentolamine Ophthalmic Solution, Presbyopia, FDA Approval, Ophthalmology, Near Vision, Eye Drops, VEGA-2, VEGA-3, Phase 3 Clinical Trials

RESEARCH TRIANGLE PARK, N.C., October 16, 2026 Opus Genetics, Inc. (NASDAQ: IRD), a clinical-stage biopharmaceutical company developing gene therapies...